-
Most Recent
Penny Stocks
Penny stocks trade at less than $5 per share. They are highly volatile and incredibly risky investments that can burn new and seasoned investors alike; they often serve as the playground for scam artists and market manipulators. However, while penny stocks can be halved in the blink of an eye, they can also double much more quickly than large-cap stocks. Investors interested in penny stocks should be aware of the risks and do their due diligence before making an investment. Read on to find out how to profit without getting scammed.
7 Space Exploration Stocks That Could Pioneer New Frontiers
Explore space exploration stocks with potential for significant growth as global competition in space technology increases.
3 Stocks to Buy That Could Turn Your Beer Money Into Champagne Showers
These three high-potential stocks could potentially turn a small investment into significant returns. Consider throwing in some beer money.
3 Stocks Under $15 That Could Make You a Millionaire
Investors looking for millionaire status in the coming years should consider three stocks under $15 that could be worth buying.
Other Stock Types you might be interested in
Recent Penny Stocks Articles
Why Is iCoreConnect (ICCT) Stock Up 19% Today?
iCoreConnect stock is rallying on Wednesday as investors in ICCT shares celebrate the company's acquisition of Verifi Dental.
Why Is Nvni (NVNI) Stock Up 64% Today?
Nvni stock is taking off on Wednesday alongside heavy trading of the company's shares despite a lack of news this morning.
Why Is Mullen Automotive (MULN) Stock Up 10% Today?
MULN stock is rising higher following the debut of Mullen's FIVE RS production design at CES 2024. Here's what you need to know.
NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation
NEXI stock is rising higher ahead of a potential liquidation and dissolution of NexImmune. Here's what you need to know.
Rent the Runway Layoffs 2024: What to Know About the Latest RENT Job Cuts
Rent the Runway layoffs are a hot topic among traders on Tuesday as the company prepares to cut 10% of its workers in a restructuring.
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?
Cyclacel Pharmaceuticals stock is slipping on Tuesday after shares of CYCC rallied on Monday alongside it regaining Nasdaq compliance.
Why Is Elicio Therapeutics (ELTX) Stock Up 11% Today?
Elicio Therapeutics stock is up with heavy trading of ELTX shares are posting positive preliminary results from a Phase 1 clinical trial.
Why Is Sentage (SNTG) Stock Up 86% Today?
Sentage stock is rising higher on Tuesday without any clear news despite shares of SNTG experiencing incredibly heavy trading this morning.
MULN Stock: Mullen Seeks New Department of Energy Grant for Battery Materials
Mullen has submitted a concept paper to the U.S. Department of Energy requesting $50 million in funding for its battery initiatives.
Needham Is Pounding the Table on Blink Charging (BLNK) Stock
One Wall Street analyst just issued a bullish price target for Blink Charging. Here's why experts believe BLNK stock could be a 2024 winner.
Why Is LumiraDx (LMDX) Stock Down 13% Today?
LumiraDx stock is falling hard on Monday as investors in LMDX prepare for the company's shares to be delisted on Tuesday!
Knightscope (KSCP) Stock Pops 6% on Announcement of New Orders
Although Knightscope enjoyed a credibility lift with three new orders, KSCP stock still represents a high-risk venture.
Can Canoo (GOEV) Stock Really Rally 1,800% From Here?
GOEV stock just got a major boost from Wedbush analyst Dan Ives, who has a price target of $4 and an "outperform" rating on Canoo.
Why Is Revelstone Capital (RCAC) Stock Up 90% Today?
Shares of RCAC stock are absolutely skyrocketing today, as the company cancels its shareholder meeting to approve a key merger.
HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy
Humanigen stock is falling hard on Friday as investors in HGEN sell shares after the company announced a bankruptcy filing.
AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts
AlloVir layoffs are coming for 95% of the company's employees as a way to reduce costs and preserve cash after failed clinical trials.
